{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-004701","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.415991+00:00","generated_at":"2026-06-19T03:47:16.659151+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel Q4 revenue $52.7M record; net income up 31%; 2023 guidance $180-188M","bullets":["Q4 total revenue $52.7M (+11% YoY); MACI revenue $46.3M (+24% YoY); Epicel $6.3M.","Q4 net income $5.9M ($0.12 diluted) vs $4.5M ($0.09) a year ago; adjusted EBITDA $14.9M (28% margin).","Full-year 2022 total revenue $164.4M; net loss $16.7M ($0.35 diluted); adjusted EBITDA $24.2M (15% margin).","2023 guidance: total revenue $180-188M, MACI $152-156M, burn care $28-32M, gross margin high-60%.","FDA approved NexoBrid for eschar removal; U.S. commercial launch expected Q2 2023; arthroscopic MACI on track for 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-004701","json":"https://secwatch.observer/filing/0001628280-23-004701.json","markdown":"https://secwatch.observer/filing/0001628280-23-004701.md","text":"https://secwatch.observer/filing/0001628280-23-004701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828023004701/0001628280-23-004701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828023004701/vcel-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:47:16.659151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}